Breaking News
November 21, 2018 - New research project to combat obesity, type 2 diabetes receives NIH funding
November 21, 2018 - Humans play key role in distribution and transmission of Bartonella bacteria
November 21, 2018 - First modeling system developed for testing age-specific human immune responses to vaccines
November 21, 2018 - FDA Alert: Gilenya (fingolimod): Drug Safety Communication
November 21, 2018 - Uric Acid Test: MedlinePlus Lab Test Information
November 21, 2018 - Researchers use genetics to predict response to antipsychotic medications
November 21, 2018 - Proposal to include the price of drugs in television ads is flawed, Stanford scholar writes
November 21, 2018 - Disrupting reproduction strategy of disease-causing parasites could help fight malaria
November 20, 2018 - ACAAI: Almost 2 Percent of Children Have Milk Allergy
November 20, 2018 - Congenital anomalies of kidney and urinary tract – Genetics Home Reference
November 20, 2018 - Can video games improve the health of older adults with schizophrenia?
November 20, 2018 - Can flicking a molecular switch restore the aging immune system’s competence?
November 20, 2018 - Restek launches new Oregon cannabis pesticide standards
November 20, 2018 - Health sector coalition urges Government to safeguard patients in future UK-EU relationship
November 20, 2018 - Study evaluates second-hand marijuana smoke exposure among children
November 20, 2018 - Scientists identify three genes responsible for recurrent molar pregnancies
November 20, 2018 - Researchers identify multisystem disorder caused by bi-allelic variants in CCDC47 gene
November 20, 2018 - Dining Out With Allergies Is Tough, But These Steps Can Help
November 20, 2018 - Breastfeeding protects infants from antibiotic-resistant bacteria
November 20, 2018 - AI matched, outperformed radiologists in screening X-rays for certain diseases | News Center
November 20, 2018 - Adolescents increasingly choose marijuana over cigarettes, alcohol
November 20, 2018 - World’s first medical imaging scanner produces diagnostic scan of the whole human body
November 20, 2018 - Cytocybernetics receives NIMH award to move into neuronal drug development
November 20, 2018 - ‘Unknown’ enzyme may be key to new treatment for inflammatory diseases
November 20, 2018 - Recreational drug may help people regain trust in others
November 20, 2018 - Researchers identify gene vital for post-stroke recovery
November 20, 2018 - Scientists identify novel target for neuron regeneration, functional recovery in spinal cord injury
November 20, 2018 - Potential new therapeutic approach developed for synovial sarcoma
November 20, 2018 - Skeletal imitation reveals how bones grow atom-by-atom
November 20, 2018 - Autism behaviors show unique brain network fingerprints in infants
November 20, 2018 - Location matters for inflammation clearance
November 20, 2018 - Towards finding a druggable cancer target
November 20, 2018 - Ultragenyx Announces Intent to Submit New Drug Application to U.S. FDA for UX007 for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Mid-2019
November 20, 2018 - Cooling ‘brains on fire’ to treat Parkinson’s
November 20, 2018 - Less pollution could increase the average lifespan of Copenhageners by an entire year in 2040
November 20, 2018 - Abramson Cancer Center becomes the 28th member institution of National Comprehensive Cancer Network
November 20, 2018 - The plug and play time-resolved spectrometer from PicoQuant
November 20, 2018 - Breakthrough technology offers new hope to people with glaucoma, retinitis and macular degeneration
November 20, 2018 - New report highlights key focus areas to help cancer screening realize its full potential
November 20, 2018 - International experts to discuss strategies to maintain spatial orientation in old age
November 20, 2018 - Low-protein, high-carb diet may promote healthy brain ageing
November 20, 2018 - Scientists discover new inhibitor that decreases lung inflammation
November 20, 2018 - Participation project calls for relaxing research ban on germline interventions
November 20, 2018 - Karyopharm’s Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
November 20, 2018 - Arthritis by the Numbers: Book of Trusted Facts & Figures
November 20, 2018 - Drug homing method helps rethink Parkinson’s
November 20, 2018 - AHF commends the passage of global AIDS funding in the House, calls for swift approval
November 20, 2018 - The search for new psychiatric disorder treatments
November 20, 2018 - New research offers hope for simpler way to diagnose and treat cancer
November 20, 2018 - Study sheds light on the infection mechanism of influenza virus
November 20, 2018 - Storage failures of eggs and embryos gain a new perspective
November 20, 2018 - Buyers of short-term health plans: Wise or shortsighted?
November 20, 2018 - Study indicates that frogs in virus-exposed groups breed at young age
November 20, 2018 - FDA Alerts Health Care Professionals and Patients Not To Use Sterile Drug Products from Pharm D Solutions
November 20, 2018 - Asthma may contribute to childhood obesity epidemic
November 20, 2018 - Live probiotics can change existing gut flora and alter immune response
November 20, 2018 - Researchers to explore the enigmatic role of unstructured protein in regulating circadian function
November 20, 2018 - Many patients with adenomas do not receive colonoscopy within recommended time frame
November 20, 2018 - Drug used to treat PTSD does not reduce suicidal thinking, may worsen nightmares and insomnia
November 20, 2018 - In-person social contact may offer protection against depression and PTSD symptoms
November 20, 2018 - Routine HCV testing in correctional facilities can best identify and treat disease, say researchers
November 20, 2018 - Molecular DNA analysis could facilitate more accurate prognosis, treatment of aggressive brain tumors
November 20, 2018 - Breast Cancer Recurrence Rate Not Up With Autologous Fat Transfer
November 20, 2018 - Beta 2 Microglobulin (B2M) Tumor Marker Test: MedlinePlus Lab Test Information
November 20, 2018 - Could bariatric surgery make men more virile?
November 20, 2018 - Urine test to check if patients take their medications will save the NHS money, say researchers
November 20, 2018 - Study reveals impact of residual inflammatory risk on clinical outcomes after PCI
November 20, 2018 - RNAi therapy shown to alleviate preeclampsia
November 20, 2018 - Replacement of dysfunctional microglia has therapeutic potential for neurodegenerative diseases
November 20, 2018 - Forming 3D Neuronal Models of the Brain
November 20, 2018 - Shoulder ultrasounds could be used to predict diabetes
November 20, 2018 - SGLT2 Inhibitors for Diabetes Linked to Increased Risk for Amputation
November 20, 2018 - Stem cell transplant cements Arizona men’s father-son bond
November 20, 2018 - Scientists try to develop portable systems that can quickly produce biologics on demand
November 20, 2018 - Automating Data Capture and Image Analysis in Continuous Experiments
November 20, 2018 - New drug shows promise for treating people with peanut allergy
November 20, 2018 - Researchers develop novel mouse model to study immunomodulatory therapies
November 20, 2018 - “Britain must not go backward on antibiotic controls to appease US trade deals” – Jim Moseley, CEO of Red Tractor
November 20, 2018 - Widespread errors in ‘proofreading’ cause inherited blindness
November 20, 2018 - Reaping the benefits of living longer
FDA: Many Questions on Novel Opioid Withdrawal Drug

FDA: Many Questions on Novel Opioid Withdrawal Drug

image_pdfDownload PDFimage_print

WASHINGTON — FDA staff expressed numerous concerns about the safety and efficacy of lofexidine, a novel non-opioid drug intended to treat symptoms of opioid withdrawal, in briefing documents prepared for an advisory committee meeting on Tuesday.

Among them: the drug’s trials focused only on short-term use in patients quitting opioids abruptly, raising questions as to whether it would be of any use in other, arguably more common situations including opioid taper.

And the review pointed up several adverse cardiovascular effects seen in the trials, including bradycardia and hypotension.

If approved, lofexidine — developed by Lexington, Ky.-based US WorldMeds with a proposed trade name of Lucemyra — would become the first non-opioid medication approved to treat opioid withdrawal and the first drug approved to help patients successfully terminate their opioid discontinuation treatment.

The Psychopharmacologic Drugs Advisory Committee is scheduled to vote on two overarching questions:

  • Whether “the data provide substantial evidence of effectiveness” for relieving opioid withdrawal symptoms
  • Whether the drug should be approved for this purpose in the context of abrupt opioid discontinuation

The committee is also being asked to discuss the drug’s potential to help patients withdraw completely from opioid dependence, according to the FDA’s meeting materials.

Other topics the committee is schedule to address:

  • Dosing recommendations
  • Whether the available safety data regarding the medication is substantial enough “to support use between 7 and 14 consecutive days”
  • Issues to be addressed in post-marketing studies

Lofexidine is an alpha-2 adrenergic agonist — similar to clonidine, which FDA staff noted is often used off-label for opioid withdrawal symptoms — slated to be part of a long-term treatment plan when patients stop using opioids.

The new medication’s evidence base is limited to two “brief” inpatient studies of OUD patients who suddenly stopped using short-acting opioids, according to the FDA staff review.

US WorldMeds said the studies demonstrate the drug’s ability to reduce opioid withdrawal symptoms in this situation, and that the drug “increases the likelihood that the course of withdrawal treatment will be completed, and the patient will reach a state of no longer being physically dependent.”

“But,” the FDA briefing document noted, “how can we interpret the information on symptomatic relief to determine whether the effect is not just statistically significant, but clinically significant? How do we know if the drug has made enough difference to be clinically meaningful?”

Moreover, the document emphasized that the company’s studies did not directly demonstrate that the symptomatic relief “translates to improvement in completion of detoxification.”

The study data are “very limited” beyond five days of dosing and does not detail the effects of administering the smaller dosages studied in other, older medical literature.

In addition, FDA staff noted that dropout rates in the two studies were very high — well over half by day 7 in the lofexidine groups, although discontinuations were even more common in the placebo groups.

Concerning side effects and adverse events, lofexidine “causes clinically significant hypotension, bradycardia, and orthostatic hypotension in a dose-dependent fashion,” according to the briefing document’s safety summary.

The United Kingdom approved lofexidine in the mid-1980’s to relieve symptoms “in patients undergoing opiate detoxification,” with patients in the 1990’s typically taking doses between 1.6-2.2 mg for a median of 10 days.

The FDA committee is chaired by Rajesh Narendran, MD, a University of Pittsburgh psychiatrist. The FDA is not obliged to follow its advisory committees’ recommendations but it usually does.

1969-12-31T19:00:00-0500

last updated

Tagged with:

About author

Related Articles